Air pollution is a global health concern, with over 90% of the world's population breathing air that exceeds World Health ...

Since the February update, an additional 5 patients have been dosed, resulting in 2 Complete Responses (CR) and 3 Partial ...

A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

Interleukin-2 (IL-2) inhibitors are immunosuppressive agents that block the activity of IL-2, a cytokine involved in the activation and proliferation ...

Calidi Biotherapeutics Inc. has spent over 10 years developing a groundbreaking platform for the systemic delivery of genetic medicines that can precisely target tumors. One of the company's core ...

Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a ...

Researchers from UCLA published a Perspective in Science Bulletin proposing bioengineered platforms that mimic immunological synapses to improve CAR-T cell manufacturing. Their strategies offer ...

Findings indicate that frequent COVID-19 booster shots do not weaken T-cell responses, alleviating concerns for vulnerable groups facing new variants.

Modified, autologous T-cell immunotherapies have been transformative in the treatment of hematologic malignancies with several approvals of chimeric antigen receptor T-cell therapies to treat lymphoma ...

γ9δ2 T-cell activation (γδTCA) with ICT01 combined with azacitidine-venetoclax (AV) for older/unfit adults with newly diagnosed (ND) AML: Preliminary efficacy and dose selection in phase 1/2 study ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced (armore ...